Compare FPH & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FPH | TECX |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | 51 |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.2M | 393.0M |
| IPO Year | 2013 | N/A |
| Metric | FPH | TECX |
|---|---|---|
| Price | $5.52 | $24.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $80.40 |
| AVG Volume (30 Days) | 192.7K | ★ 522.8K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $237,926,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | ★ 12.37 | N/A |
| 52 Week Low | $4.58 | $13.70 |
| 52 Week High | $6.64 | $27.21 |
| Indicator | FPH | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 61.31 |
| Support Level | $5.36 | $16.53 |
| Resistance Level | $5.75 | $26.24 |
| Average True Range (ATR) | 0.21 | 1.96 |
| MACD | 0.03 | 0.16 |
| Stochastic Oscillator | 63.64 | 91.95 |
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its three reportable segments are Valencia, San Francisco, and Great Park. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.